loading
Precedente Chiudi:
$14.07
Aprire:
$12.815
Volume 24 ore:
18.36M
Relative Volume:
2.66
Capitalizzazione di mercato:
$1.33B
Reddito:
$2.23B
Utile/perdita netta:
$-248.39M
Rapporto P/E:
-5.0428
EPS:
-2.69
Flusso di cassa netto:
$-697.55M
1 W Prestazione:
-29.81%
1M Prestazione:
-32.78%
6M Prestazione:
-88.44%
1 anno Prestazione:
-90.73%
Intervallo 1D:
Value
$12.60
$13.95
Intervallo di 1 settimana:
Value
$12.60
$22.86
Portata 52W:
Value
$12.60
$150.48

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Nome
Sarepta Therapeutics Inc
Name
Telefono
617-274-4000
Name
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Name
Dipendente
1,372
Name
Cinguettio
@sarepta
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
SRPT's Discussions on Twitter

Confronta SRPT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
13.52 1.89B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.84 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.43 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.08 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
567.12 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.00 27.29B 3.81B -644.79M -669.77M -6.24

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-18 Downgrade Needham Buy → Hold
2025-06-20 Downgrade William Blair Outperform → Mkt Perform
2025-06-18 Downgrade TD Cowen Buy → Hold
2025-06-17 Iniziato Wolfe Research Peer Perform
2025-06-16 Downgrade BMO Capital Markets Outperform → Market Perform
2025-06-16 Downgrade BofA Securities Buy → Neutral
2025-06-16 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-06-16 Downgrade H.C. Wainwright Neutral → Sell
2025-06-16 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-06-16 Downgrade Piper Sandler Overweight → Neutral
2025-06-06 Aggiornamento Scotiabank Sector Perform → Sector Outperform
2025-05-08 Downgrade Evercore ISI Outperform → In-line
2025-04-11 Iniziato Wells Fargo Overweight
2025-04-02 Aggiornamento H.C. Wainwright Sell → Neutral
2025-03-31 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-02-11 Iniziato Deutsche Bank Hold
2024-11-27 Reiterato Needham Buy
2024-11-25 Iniziato H.C. Wainwright Sell
2024-11-07 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-10-21 Iniziato Jefferies Buy
2024-10-10 Ripresa Raymond James Outperform
2024-07-29 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2024-06-26 Downgrade Citigroup Buy → Neutral
2024-05-31 Iniziato Piper Sandler Overweight
2024-05-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2024-05-14 Aggiornamento Oppenheimer Perform → Outperform
2024-01-31 Iniziato BMO Capital Markets Outperform
2023-12-13 Ripresa Citigroup Buy
2023-12-12 Iniziato Deutsche Bank Buy
2023-11-21 Iniziato Wedbush Outperform
2023-10-31 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-10-31 Downgrade Oppenheimer Outperform → Perform
2023-06-23 Downgrade Evercore ISI Outperform → In-line
2023-04-26 Iniziato SMBC Nikko Outperform
2023-04-04 Iniziato Citigroup Buy
2023-03-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-12-22 Reiterato BTIG Research Buy
2022-12-16 Aggiornamento UBS Neutral → Buy
2022-04-04 Ripresa Cantor Fitzgerald Overweight
2022-01-05 Reiterato Needham Buy
2021-12-09 Aggiornamento Oppenheimer Perform → Outperform
2021-11-05 Aggiornamento JP Morgan Neutral → Overweight
2021-09-15 Aggiornamento Guggenheim Neutral → Buy
2021-08-05 Aggiornamento JP Morgan Underweight → Neutral
2021-06-15 Iniziato BTIG Research Buy
2021-04-26 Ripresa Credit Suisse Neutral
2021-01-12 Downgrade Citigroup Buy → Neutral
2021-01-11 Downgrade UBS Buy → Neutral
2021-01-08 Downgrade JP Morgan Overweight → Underweight
2021-01-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-01-08 Downgrade Raymond James Outperform → Mkt Perform
2020-11-11 Iniziato Berenberg Hold
2020-10-28 Iniziato UBS Buy
2020-08-25 Iniziato Raymond James Outperform
2020-08-20 Downgrade Credit Suisse Outperform → Neutral
2020-03-31 Iniziato Mizuho Buy
2019-11-01 Iniziato Guggenheim Buy
2019-08-21 Reiterato Needham Buy
2019-07-09 Reiterato Morgan Stanley Overweight
2019-07-01 Reiterato RBC Capital Mkts Outperform
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-11 Reiterato Credit Suisse Outperform
2018-10-12 Iniziato Bernstein Outperform
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-09-26 Reiterato RBC Capital Mkts Outperform
2018-09-14 Ripresa BofA/Merrill Buy
2018-09-06 Iniziato Credit Suisse Outperform
2018-08-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-06-21 Reiterato Robert W. Baird Outperform
2018-06-20 Reiterato Needham Buy
2018-06-19 Reiterato H.C. Wainwright Buy
Mostra tutto

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

pulisher
11:12 AM

Sarepta Is Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says - Bloomberg.com

11:12 AM
pulisher
10:42 AM

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma

10:42 AM
pulisher
10:35 AM

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia

10:35 AM
pulisher
10:15 AM

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

10:15 AM
pulisher
10:10 AM

Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com

10:10 AM
pulisher
09:47 AM

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance

09:47 AM
pulisher
09:39 AM

Sarepta Dives, Again, As Its 'Unprecedented Times' Continue - Investor's Business Daily

09:39 AM
pulisher
09:32 AM

Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView

09:32 AM
pulisher
09:03 AM

Sarepta Stock Sinks. How Its Crisis Went From Bad to Worse. - Barron's

09:03 AM
pulisher
08:57 AM

Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes

08:57 AM
pulisher
08:45 AM

Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar

08:45 AM
pulisher
07:54 AM

Sarepta Stands Ground Against HHS Request to Stop Elevidys Shipments - BioSpace

07:54 AM
pulisher
07:54 AM

Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha

07:54 AM
pulisher
07:53 AM

Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com

07:53 AM
pulisher
07:45 AM

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Benzinga

07:45 AM
pulisher
07:36 AM

SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile

07:36 AM
pulisher
07:33 AM

Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com

07:33 AM
pulisher
06:57 AM

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider

06:57 AM
pulisher
06:12 AM

Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha

06:12 AM
pulisher
02:44 AM

Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Needham & Company LLC - Defense World

02:44 AM
pulisher
02:43 AM

Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $41.00 - Defense World

02:43 AM
pulisher
02:43 AM

Bank of America Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00 - Defense World

02:43 AM
pulisher
01:22 AM

Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings - Defense World

01:22 AM
pulisher
12:17 PM

What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia

12:17 PM
pulisher
Jul 20, 2025

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 20, 2025
pulisher
Jul 20, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News

Jul 20, 2025
pulisher
Jul 19, 2025

This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline

Jul 19, 2025
pulisher
Jul 19, 2025

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP

Jul 19, 2025
pulisher
Jul 19, 2025

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance

Jul 19, 2025
pulisher
Jul 19, 2025

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha

Jul 19, 2025
pulisher
Jul 19, 2025

Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters

Jul 19, 2025
pulisher
Jul 18, 2025

Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County - 10TV

Jul 18, 2025
pulisher
Jul 18, 2025

Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ - MedCity News

Jul 18, 2025
pulisher
Jul 18, 2025

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Is Sarepta Therapeutics Inc. a good long term investmentOutstanding capital growth - Jammu Links News

Jul 18, 2025

Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.67
price down icon 1.03%
$35.60
price up icon 0.17%
$102.58
price down icon 0.03%
$26.88
price up icon 1.05%
$110.44
price down icon 0.20%
biotechnology ONC
$290.46
price down icon 1.81%
Capitalizzazione:     |  Volume (24 ore):